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BACKGROUND: Mitral regurgitation is the most common heart valve disease in the general population, but
little is known about the prevalence and prognostic implications of mitral regurgitation in patients with type
2 diabetes.
METHODS: We retrospectively analyzed the data from 814 outpatients with type 2 diabetes who had un-
dergone a conventional echocardiography for clinical reasons during the years 1992-2007. Mitral regur-
gitation was evaluated by using an integrated multiparametric echocardiographic approach. The study
outcomes were all-cause and cardiovascular mortality.
RESULTS: At baseline, 261 (32%) patients had mitral regurgitation (25% mild, 5% moderate, and 2% se-
vere). Over a mean follow-up of 9 years, 120 (14%) patients died, 50 of them from cardiovascular causes.
Compared with those without valve disease, patients with mild mitral regurgitation had a 3.3-fold increased
risk of all-cause mortality, whereas those with moderate-to-severe mitral regurgitation had a 5.1-fold
increased risk of all-cause mortality. Results remained statistically signiﬁcant after adjustment for multi-
ple potential confounders. Similar results were found for cardiovascular mortality.
CONCLUSIONS: Mitral regurgitation is a common pathologic condition in patients with type 2 diabetes and
is independently associated with an increased risk of both all-cause and cardiovascular mortality, even if the
severity of mitral regurgitation is mild.
 2016 Elsevier Inc. All rights reserved.  The American Journal of Medicine (2017) 130, 70-76
KEYWORDS: Cardiovascular disease; Mitral regurgitation; Mortality; Type 2 diabetesMitral regurgitation is the most common heart valve ab-
normality encountered in clinical practice.1,2 Epidemiologic
studies show that moderate or severe mitral regurgitation is
signiﬁcantly associated with cardiac remodeling/dysfunction
and excess mortality.1,2
To date, little attention has been paid to analyzing the
characteristics of mitral regurgitation in patients with type
2 diabetes, who are at high cardiovascular risk ande.
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0.1016/j.amjmed.2016.07.016commonly have mitral valve calciﬁcation.3,4 In addition, no
large observational studies have explored the prognostic
impact of the severity of mitral regurgitation on mortality
outcomes in this patient population.
Therefore, the main aim of this observational study was
to estimate the prevalence of mitral regurgitation, and to
examine the long-term prognostic role of this valve abnor-
mality on the risk of all-cause and cardiovascular mortality
in a large cohort of type 2 diabetic individuals.METHODS
Patients
The study was performed within the frame of the Verona
Diabetes Study, an observational longitudinal study on
Rossi et al Mitral Regurgitation in Type 2 Diabetes 71chronic complications in outpatients with type 2 diabetes.3
We retrospectively analyzed the electronic records of all
White type 2 diabetic outpatients, who regularly attended
the diabetes clinic at the University Hospital of Verona
during the years 1992-2007. Of these, we selected all pa-
tients with type 2 diabetes who had undergone a ﬁrst con-CLINICAL SIGNIFICANCE
 Mitral regurgitation is frequent in pa-
tients with type 2 diabetes mellitus.
 Main causes are valve alteration and
impairments of regional or global left
ventricular function.
 Mitral regurgitation is a predictor of all-
cause mortality and cardiovascular
mortality.ventional echocardiography for
any clinical reasons (eg, dyspnea,
palpitations, chest pain, history of
myocardial infarction, electrocar-
diographic abnormalities, assess-
ment of left ventricular wall
thickness, presence of multiple
cardiovascular risk factors) at our
institution during the same period
of time. Thus, 814 type 2 diabetic
outpatients were identiﬁed and
included in ﬁnal analysis.
The local ethics committee
approved the study protocol. The
informed consent requirement for
this study was exempted by the ethics committee because
researchers only accessed retrospectively a de-identiﬁed
database for analysis purposes.Clinical and Laboratory Data
A detailed clinical history was recorded in each patient.
Body mass index was measured as kilograms divided by the
square of height in meters. A physician measured blood
pressure in duplicate with a mercury sphygmomanometer.
Subjects were considered to have hypertension if their blood
pressure was 140/90 mm Hg or if they were taking any
antihypertensive drugs. Dyslipidemia was deﬁned as total
cholesterol concentrations > 200 mg/dL or use of any lipid-
lowering drugs. Presence of a previous history of cardiac
diseases (ie, myocardial infarction, angina, or revasculari-
zation procedures) was also recorded from clinical charts.
Serum lipids, creatinine, glucose, and other biochemical
blood measurements were determined in the same labora-
tory using standard laboratory procedures. Hemoglobin
A1c was measured by an automated high-performance
liquid chromatography analyzer. Estimated glomerular
ﬁltration rate (eGFR) was calculated from the 4-variable
Modiﬁcation of Diet in Renal Disease study equation. Uri-
nary albumin excretion rate was measured from a 24-hour
urine sample using an immunonephelometric method. The
diagnosis of diabetic retinopathy was based on fundoscopy
by a single ophthalmologist.Transthoracic Echocardiography
All echocardiographic examinations were performed at our
institution by experienced cardiologists. Left ventricular
chamber dimensions and wall thickness were measure from
M-mode recordings and left ventricular mass was calculated.
Ejection fraction was either measured from left ventriculardiameters or 2-dimensional area changes in systole and
diastole, or estimated visually, a method comparable with
other modalities for ejection fraction assessment.5 Regional
left ventricular function was evaluated by means of wall
motion score index (WMSI) on the basis of its motion and
systolic thickening. Left ventricular segments were scored asfollows: 1 ¼ normal; 2 ¼ hypo-
kinetic; 3 ¼ akinetic; and
4 ¼ dyskinetic or aneurysmatic.
WMSI was derived as the sum of
all scores divided by the number of
ventricular segments visualized.
Aortic-valve sclerosis was deﬁned
as focal or diffuse calciﬁcation and
thickening of aortic valve leaﬂets
with or without restriction of leaﬂet
motion on echocardiography.3
Mitral valve abnormalities were
considered as follows: nonspeciﬁc
mitral valve leaﬂet thickening,
mitral annulus calciﬁcation, mitralvalve prolapse, or rheumatic valve disease. The severity of
mitral regurgitation was assessed by an integration of color
Doppler jet area, vena contracta, or proximal isovelocity
surface area and graded from 0 to 3 (ie, none, mild, moderate
and severe).Mortality Follow-Up Data
Vital status on September 30, 2007 was ascertained for all
patients through examination of the electronic databases of
the Social Health Unit of the Veneto Region, which include
all records of death as well as the speciﬁc causes of death.
Death certiﬁcates were coded by trained nosologists using
the International Classiﬁcation of Diseases, Ninth Revision;
death was attributed to cardiovascular causes when these
codes were 390-459. A selected sample of death certiﬁcates
was reviewed manually to validate the process.Statistical Analysis
Data are presented as means  SD or percentages. Skewed
variables were logarithmically transformed to improve
normality prior to analysis. Comparisons between groups
were made using the one-way analysis of variance and the
chi-squared test. Given the low number of patients with
severe mitral regurgitation (n ¼ 18), we merged patients
with either moderate or severe mitral regurgitation into a
single subgroup. Univariate survival analysis was performed
by the Kaplan-Meier analysis; the overall signiﬁcance was
calculated by the log-rank test. Cox regression analysis was
used to determine the association between the severity of
mitral regurgitation and risk of all-cause and cardiovascular
mortality after adjustment for multiple potential
confounders.
Three forced-entry Cox regression models were per-
formed: an unadjusted model; a model adjusted for age
72 The American Journal of Medicine, Vol 130, No 1, January 2017(model 1); and, ﬁnally, a model adjusted for age, sex, dia-
betes duration, dyslipidemia, hypertension, eGFR, WMSI
score, ejection fraction 50%, presence of aortic-valve
sclerosis, or mitral valve abnormalities (model 2). The
covariates included in these regression models were chosen
as potential confounding factors on the basis of their bio-
logical plausibility or their signiﬁcance in univariable ana-
lyses (see Appendix, Supplementary Table, available
online). Results of Cox proportional hazard models were
presented as hazard ratios and 95% conﬁdence intervals.
Analyses were performed using statistical package SPSS
19.0 (IBM, Armonk, NY) and statistical signiﬁcance was
assessed at the 2-tailed P <.05 threshold.RESULTS
Among the 814 patients included in the study, 261 (32%)
patients had any degree of mitral regurgitation: 203 (25%)
patients had mild mitral regurgitation, and 58 (7%) had
moderate or severe mitral regurgitation. Overall, 596 (73%)Table 1 Baseline Clinical, Biochemical, and Echocardiographic Cha
Echocardiographic Severity of Mitral Regurgitation (MR)
Overall
Population
Withou
Regurgi
n 814 553
Age (y) 68  9 67 
Female sex (%) 37 54
Body mass index (kg/m2) 28  5 29 
Systolic blood pressure (mm Hg) 139  18 137 
Diastolic blood pressure (mm Hg) 80  9 80 
Hypertension (%) 90 88
Smoking history (%) 25 25
Dyslipidemia (%) 27 28
HDL cholesterol (mmol/L) 1.34  0.39 1.33 
LDL cholesterol (mmol/L) 3.31  0.88 3.28 
Triglycerides (mmol/L) 1.75  1.22 1.82 
eGFR (mL/min/1.73 m2) 65  18 67 
Fasting glucose (mmol/L) 9.04  2.90 9.15 
HbA1c (%) 7.72  1.59 7.74 
Diabetes duration (y) 15  9 15 
Albuminuria (mg/L) 60  130 67 
Diabetic retinopathy (%) 32 29
Ejection fraction (%) 57  13 59 
Ejection fraction 50% (%) 20 14
Left ventricular diastolic diameter (mm) 52  7 51 
Left ventricular systolic diameter (mm) 33  8 32 
Left ventricular mass (g) 244  82 241 
WMSI score 1.1  0.4 1.13 
WMSI >1 (%) 33 26
Aortic-valve sclerosis (%) 41 32
Known cardiac diseases (%) 40 35
Prior myocardial infarction (%) 24 20
Mitral valve abnormalities (%) 27 19
Data are expressed as means  SD and relative frequencies.
Note: Information on smoking history was available for only 516 patients.
eGFR ¼ estimated glomerular ﬁltration rate; HbA1c ¼ hemoglobin A1c; HDL
motion score index.patients had morphologically normal mitral valve, 144
(18%) patients had isolated calciﬁcation of the mitral valve,
and 74 (9%) patients had other mitral valve abnormalities/
diseases (eg, nonspeciﬁc mitral leaﬂet thickening, mitral
prolapse, or rheumatic mitral valve disease). In addition,
among patients without cardiac/ischemic diseases (n¼ 485),
the overall prevalence of mitral regurgitation was 28%,
whereas the prevalence of this valve abnormality was 39%
among patients with established cardiac/ischemic diseases.
As shown in Table 1, patients with increasing severity
of mitral regurgitation were older and more likely to be
male. They also had higher values of WMSI score,
cardiac mass, and hemoglobin A1c levels, and lower
values of eGFR and ejection fraction. The prevalences of
prior cardiac/ischemic diseases and mitral valve
abnormalities also increased progressively with the
severity of mitral regurgitation. However, mitral valve
abnormalities were also found in 19% of patients without
mitral regurgitation. No signiﬁcant differences were
found in terms of conventional cardiovascular riskracteristics of Patients with Type 2 Diabetes Stratiﬁed by the
t Mitral
tation
Mild Mitral
Regurgitation
Moderate-Severe
Mitral Regurgitation P Value
203 58
8 69  8 71  8 <.001
43 9 <.001
4 28  5 29  5 .14
18 140  18 142  20 .09
10 80  9 79  10 .46
90 91 .73
33 33 .90
24 34 .32
0.39 1.37  0.42 1.31  0.33 .42
0.90 3.35  0.84 3.39  0.83 .50
1.36 1.63  0.89 1.52  0.61 .056
18 64  20 59  19 <.05
2.91 8.71  2.84 9.17  2.92 .22
1.53 7.54  1.59 8.11  2.06 .05
9 15  9 17  8 .25
143 43  93 60  108 .20
29 47 .07
11 53  13 47  16 <.001
29 55 <.001
6 53  7 55  10 <.005
7 35  9 36  14 <.01
78 247  88 273  105 .21
0.28 1.26  0.40 1.49  0.54 <.001
42 55 <.001
58 62 <.001
48 60 <.001
32 27 <.01
33 67 <.001
¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; WMSI ¼ wall
Rossi et al Mitral Regurgitation in Type 2 Diabetes 73factors, duration of diabetes, and diabetic retinopathy
between the groups. At multivariate logistic regression
analysis, male sex, higher body mass index, lower
ejection fraction, and presence of mitral valve
abnormalities were independently associated with a
greater severity of mitral regurgitation (data not shown).
Interestingly, 376 (46%) patients had morphologically
normal mitral valve and normal ventricular global and
regional systolic function of whom 61 had mild mitral
regurgitation and only 2 had moderate-to-severe valve
disease.Survival Analysis
During a mean follow-up period of 9 years, 120 (14%)
patients died, 50 of them from cardiovascular causes.
As shown in the Figure, the severity of mitral
regurgitation was signiﬁcantly associated with an
increased risk of all-cause mortality. For example, at 10
years of follow-up, patients without mitral regurgitation
had a survival rate of w90%, those with mild mitral
regurgitation of 69%, and those with moderate-to-severe
mitral regurgitation of 47% (P <.001 for differences by
the log-rank test). Notably, after excluding patients with
moderate-to-severe mitral regurgitation, the survival rates
for patients with mild mitral regurgitation and those
without valve disease remained signiﬁcantly different
(P <.001 by the long rank test). The univariable Cox
regression analysis (Table 2, ﬁrst column) revealed that
compared with patients without mitral regurgitation, those
with mild mitral regurgitation had a 3.31-fold increased
risk of all-cause mortality, whereas patients with moderate-
to-severe mitral regurgitation had a 5.1-fold increased risk
of all-cause mortality. Similar results were found for car-
diovascular mortality. The Supplementary Table (Appen-
dix, available online) shows other univariable signiﬁcant
predictors of all-cause mortality considered as covariates in
multivariable regression models.Figure Kaplan-Meier survival analysis for all-cause mor-
tality in 814 outpatients with type 2 diabetes stratiﬁed by
mitral regurgitation severity at baseline.As also shown in Table 2 (second and third columns),
the signiﬁcant and positive relationships between the
severity of mitral regurgitation and the risk of both all-
cause and cardiovascular mortality were little affected by
adjustment for age, sex, diabetes duration, dyslipidemia,
hypertension, eGFR, WMSI score, ejection fraction 50%,
and presence of aortic-valve sclerosis and mitral valve ab-
normalities (adjusted model 1 and 2). Further adjustment for
smoking history did not change these results, although the
strength of associations between moderate-to-severe mitral
regurgitation and mortality risk was attenuated, possibly due
to the smaller number of patients included in the ﬁnal
multivariate regression model (ie, information on smoking
status was available in only 516 patients). Other variables
that were independently associated with higher all-cause and
cardiovascular mortality in the fully adjusted regression
model were older age, longer duration of diabetes, presence
of aortic-valve sclerosis, and lower eGFR values; mitral
valve abnormalities and hypertension were also indepen-
dently associated with higher all-cause mortality but not
with cardiovascular mortality (data not shown).
We conducted sensitivity analyses to evaluate the
robustness of our ﬁndings. As shown in Table 3, the
severity of mitral regurgitation was signiﬁcantly associated
with higher all-cause mortality in all subgroups evaluated,
except for a borderline signiﬁcance in patients with both
mild mitral regurgitation and mitral valve abnormalities.
Finally, among the 376 patients who had morphologi-
cally normal mitral valve and normal systolic function, the
presence of mild mitral regurgitation was signiﬁcantly
associated with higher all-cause mortality (hazard ratio 3.21;
95% conﬁdence interval, 1.6-6.7; P ¼ .001). Similar results
were also found for cardiovascular mortality (data not
shown).DISCUSSION
To our knowledge, this is the ﬁrst observational study to
speciﬁcally address the prognostic role of mitral regurgita-
tion in predicting all-cause and cardiovascular mortality in a
large cohort of type 2 diabetic outpatients referred for
clinically indicated echocardiograms.
The main ﬁndings of our study were that: 1) the overall
prevalence of mitral regurgitation was very high (32%) in
this patient population, even in patients without established
cardiac/ischemic heart diseases (28%); 2) mitral valve ab-
normalities and the WMSI score were the strongest de-
terminants of mitral regurgitation; and 3) the severity of
mitral regurgitation, even if mild, was strongly and pro-
gressively associated with an increased risk of both all-cause
and cardiovascular mortality, independently of multiple
potential confounders.
Although the overall prevalence of mitral regurgitation
in this study was high, it is important to remark that most
of our patients had mild mitral regurgitation. This is
important because mild mitral regurgitation is clinically
silent and often remains undetected,6 highlighting the
Table 2 Univariable and Multivariable Cox Regression Models Showing the Signiﬁcant Associations Between the Severity of Mitral
Regurgitation and the Risk of Both All-Cause and CVD Mortality in Patients with Type 2 Diabetes
Cox Regression Models
Unadjusted Model P Value Adjusted Model 1 P Value Adjusted Model 2 P Value
All-cause mortality
Mitral regurgitation
Absent Ref. Ref. Ref.
Mild 3.32 (2.20-5.05) <.001 2.69 (1.77-4.10) <.001 2.33 (1.40-3.88) <.001
Moderate-severe 5.10 (2.93-8.84) <.001 4.74 (2.72-8.27) <.001 2.79 (1.25-6.24) <.01
Cardiovascular mortality
Mitral regurgitation
Absent Ref. Ref. Ref.
Mild 4.78 (3.65-12.6) <.001 5.28 (2.82-9.90) <.001 4.37 (2.08-9.21) <.001
Moderate-severe 7.42 (3.11-17.7) <.001 6.75 (2.81-16.2) <.001 5.58 (1.76-17.6) <.005
Results are expressed as odds ratios  95% conﬁdence intervals (in parenthesis) as assessed by univariable (unadjusted) or multivariable Cox regression
analyses. Rates of all-cause mortality or cardiovascular mortality were the dependent variable.
Covariates included in multivariate regression models were as follows: model 1: age; and model 2: age, sex, duration of diabetes, dyslipidemia, hy-
pertension, estimated glomerular ﬁltration rate, wall motion score index, ejection fraction 50%, and echocardiographic presence of aortic-valve sclerosis
and mitral valve abnormalities.
CVD ¼ cardiovascular disease; Ref. ¼ reference category.
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ment and stratiﬁcation of mortality in patients with type
2 diabetes.
As expected, a morphological alteration of mitral valve
leaﬂets was a strong determinant of valve insufﬁciency. We
believe that the observed signiﬁcant univariable association
between the severity of mitral regurgitation and mitral valve
abnormalities is at least partly due to the fact that mitral
valve calciﬁcation is a marker of coronary artery calciﬁca-
tion,7 and then mitral regurgitation is likely a direct conse-
quence of coronary artery disease on left ventricular
function. Accordingly, abnormal WMSI score and lower
ejection fraction were independently associated with the
presence of mitral regurgitation, and this may also explain
why most of our diabetic patients had mitral regurgitation
even with a morphologically normal valve (ie, the so-
called “functional mitral regurgitation” that occurred in upTable 3 Subgroup Analyses - Hazard Ratios for Mild and Moderate-to-S
Different Subgroups of Patients with Type 2 Diabetes
Mild Mitral Regurgitati
HR (95% CI)
Ejection fraction >50% (n ¼ 654) 3.22 (1.97-5.25)
Ejection fraction 50% (n ¼ 160) 2.81 (1.31-6.22)
Men (n ¼ 510) 3.52 (2.12-5.99)
Women (n ¼ 304) 2.73 (1.39-5.30)
Age >65 years (n ¼ 507) 2.92 (1.88-4.60)
Age 65 years (n ¼ 307) 3.53 (1.26-9.55)
Diabetes duration >16 years (n ¼ 323) 2.73 (1.39-5.57)
Diabetes duration 16 years (n ¼ 491) 3.22 (2.01-4.97)
With mitral valve abnormalities (n ¼ 217) 1.76 (0.87-3.51)
Without mitral valve abnormalities (n ¼ 597) 4.09 (2.42-6.98)
CI ¼ conﬁdence interval; HR ¼ hazard ratio.tow70% of our patients). The presence of functional mitral
regurgitation has been reported in patients with a dysfunc-
tional left ventricle (ie, dilated cardiomyopathy or acute
myocardial infarction). In these pathologic conditions,
functional mitral regurgitation is thought to be mainly due to
the dilation of mitral annulus and the tethering of the
papillary muscle, displaced by left ventricular remodeling,
on the mitral leaﬂets.8,9 Interestingly, in our study, mitral
regurgitation was also found among patients with morpho-
logically normal mitral valve and normal ejection fraction
and WMSI. It has been reported that in other clinical con-
ditions, such as aortic-valve stenosis, the degree of func-
tional mitral regurgitation is related to an impaired
longitudinal systolic function occurring in the setting of
normal WMSI and ejection fraction.10,11 Recent data also
showed that type 2 diabetic patients without established
cardiovascular disease and with normal conventionalevere Mitral Regurgitation in Predicting All-Cause Mortality Risk in
on
P Value
Moderate-severe Mitral Regurgitation
HR (95% CI) P Value
.001 3.42 (1.57-7.62) <.005
.01 5.72 (2.2-14.71) .01
<.001 4.31 (2.16-8.57) <.001
<.005 5.22 (2.05-13.3) <.001
<.001 5.23 (2.86-9.58) <.001
.01 3.84 (1.26-9.57) .06
<.005 6.24 (2.78-13.5) <.001
<.001 4.76 (2.53-8.95) <.001
.08 2.93 (1.13-5,04) <.05
<.001 8.13 (3.14-21.0) <.001
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have impaired left ventricular longitudinal contraction.12
This suggests that functional mitral regurgitation is a reli-
able marker of (early) ventricular dysfunction in patients
with type 2 diabetes, and it might partly explain the negative
impact of functional mitral regurgitation on mortality out-
comes in this patient population.
We believe that the most striking observation of our
study was the strong, graded association between the
severity of mitral regurgitation and the risk of both all-
cause and cardiovascular mortality. Notably, this associa-
tion remained statistically signiﬁcant after adjusting for
several potential confounders, including relevant echocar-
diographic parameters (ie, WMSI score, ejection fraction
50%, aortic-valve sclerosis, and mitral valve abnormal-
ities). Even more interesting is our observation that the
presence of mild mitral regurgitation was independently
associated with an increased risk of both all-cause and
cardiovascular mortality. A plausible explanation for these
ﬁndings is that a small volume overload might adversely
affect the pressure-volume relationship of the diabetic left
ventricle that frequently exhibits left ventricular diastolic
dysfunction and decreased preload reserve.13 Thus, the
presence of mitral regurgitation might displace the left
ventricular pressure-volume loop upwards, forcing the
ventricle to operate at higher ﬁlling pressure. However, we
believe that the prognostic role of mitral regurgitation
cannot be entirely explained by its adverse impact on left
ventricular volume overload; in fact, aortic valve regurgi-
tation, which causes a similar degree of volume overload,
was not independently associated with poor prognosis in
our study (data not shown). On the contrary, for the same
reason(s) explained above, we believe that functional mitral
regurgitation is a reliable marker of left ventricular
dysfunction even when ejection fraction is preserved, and
so its presence may help identify patients at increased
mortality risk.
The major limitations of our study were its retrospective,
longitudinal design, and a possible selection bias of
excluding patients who had missing echocardiographic data
at baseline. There was also a relatively small number of
clinical events during the follow-up period (ie, the cumu-
lative incidence rate of all-cause mortality was 14%
[120 total deaths]), and therefore, the results should be
interpreted with some caution. In addition, although our
statistical models were extensive, unmeasured confounders
could potentially explain the observed associations.
Another limitation of the study is that despite the quanti-
ﬁcation of mitral regurgitation severity being multi-
parametric, there was no systematic measurement of
quantitative echocardiographic parameters (eg, effective
regurgitant oriﬁce area and mitral valve regurgitant vol-
ume). As previously reported, the use of quantitative
echocardiographic parameters might provide more relevant
prognostic information.1 Thus, although our data might
have underestimated the prognostic relevance of mitral
regurgitation, the results of the present study should beconsidered as conservative estimates of the relationship
between mitral regurgitation and mortality outcomes. We
also did not have any data on left ventricular longitudinal
systolic function because this information was not consis-
tently provided in the original echo reports. In addition,
although we adjusted our results for both WMSI and
ejection fraction 50%, we did not have complete coronary
angiographic data for all patients; so the speciﬁc links of
mitral regurgitation with the severity of coronary athero-
sclerosis or mortality outcomes cannot be deﬁnitely eluci-
dated. Finally, because our cohort comprised white, type 2
diabetic individuals who were followed at an outpatient
diabetes clinic and who were referred for echocardiography
for clinical reasons, our results may not necessarily be
generalizable to other diabetic populations.
Notwithstanding these limitations, the current study has a
number of important strengths, including the large number
of patients of both sexes, the long duration of the follow-up
period, the complete nature of the dataset, and the ability to
adjust for several risk factors and potential confounders.
In conclusion, these results indicate that mitral regurgi-
tation is highly prevalent in patients with type 2 diabetes and
is independently associated with an increased risk of both
all-cause and cardiovascular mortality, even if the degree of
this valve abnormality is mild. However, further larger
studies are needed to conﬁrm the reproducibility of these
results, and to elucidate whether pharmacological in-
terventions aimed at decreasing the development and
progression of mitral regurgitation may reduce mortality
rates in patients with type 2 diabetes.SUPPLEMENTARY DATA
Supplementary table accompanying this article can be found
in the online version at http://dx.doi.org/10.1016/j.amjmed.
2016.07.016.References
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Supplementary Table Univariable Associations Between Main
Clinical, Laboratory, and Echocardiographic Variables and the
Risk of All-Cause Mortality in Patients with Type 2 Diabetes
Hazard Ratio
(95% CI) P Value
Age (y) 1.08 (1.05-1.10) <.001
Female sex (%) 1.02 (0.73-1.44) .80
Systolic blood pressure (mm Hg) 1.01 (0.99-1.01) .09
Diastolic blood pressure (mm Hg) 0.98 (0.97-1.01) .33
Hypertension (%) 1.48 (0.88-2.49) .10
Dyslipidemia (%) 1.68 (1.19-2.38) <.005
Smoking status (%)* 1.74 (1.06-3.11) <.05
Diabetes duration (y) 1.04 (1.02-1.06) <.001
eGFR (mL/min/1.73 m2) 0.97 (0.96-0.98) <.001
Fasting glucose (mmol/L) 0.96 (0.90-1.03) .23
HbA1c (%) 1.03 (0.93-1.15) .49
Left ventricular diastolic
diameter (mm)
1.01 (0.98-1.05) .20
Left ventricular systolic
diameter (mm)
1.02 (0.99-1.04) .12
Ejection fraction 50% (%) 2.04 (1.44-2.89) <.001
WMSI score 3.12 (2.01-4.75) <.001
Aortic-valve sclerosis (%) 3.20 (2.19-4.66) <.001
Mitral valve abnormalities (%) 2.48 (1.71-3.59) <.001
CI ¼ conﬁdence interval; eGFR ¼ glomerular ﬁltration rate; HbA1c ¼
hemoglobin A1c; WMSI ¼ wall motion score index.
*Information on smoking status was available for only 516 patients.
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